XML 39 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Sep. 30, 2020
Summary of Significant Accounting Policies  
Schedule of the Company's net sales by medical indication

Three Months Ended

(In thousands)

September 30, 

Medical Indication

    

2020

    

2019

Analgesic

$

3,120

$

1,884

Anti-Psychosis

13,028

28,034

Cardiovascular

 

19,714

 

21,606

Central Nervous System

22,525

19,257

Endocrinology

3,233

Gastrointestinal

17,100

16,962

Infectious Disease

21,932

11,895

Migraine

 

9,690

 

9,143

Respiratory/Allergy/Cough/Cold

1,426

2,707

Urinary

1,458

435

Other

 

7,634

 

9,861

Contract manufacturing revenue

5,619

5,558

Total net sales

$

126,479

$

127,342

Summary of products which accounted for at least 10% of total net sales

Three Months Ended

September 30, 

    

2020

    

2019

    

Product 1

 

15

%

7

%

 

Product 2

 

9

%

20

%

 

Summary of customers which accounted for at least 10% of total net sales

Three Months Ended

    

September 30, 

    

    

    

2020

    

2019

    

Customer A

 

26

%

25

%

 

Customer B

 

22

%

27

%

 

Customer C

10

%

13

%